MaxCyte vs Precipio
MaxCyte reported revenue of $33 million in fiscal 2025, 1.4 times Precipio's $24 million in fiscal 2025. MaxCyte's revenue fell 14.5% in its latest year, and Precipio's grew 29.8%. MaxCyte had an operating margin of -157.1%, against -5.0% at Precipio. Free cash flow was −$36 million at MaxCyte and $0 million at Precipio.
Side by side
| MaxCyte | Precipio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $33M | $24M |
| Revenue growth | −14.5% | 29.8% |
| Revenue growth a year, last 5 years | 4.7% | 31.5% |
| Gross margin | 81.2% | 44.5% |
| Operating margin | −157.1% | −5.0% |
| Net margin | −135.1% | −1.5% |
| Free cash flow | −$36M | $0M |
| Free cash flow margin | −109.5% | 1.5% |
| Return on capital | — | −7.8% |
| Net debt to EBITDA | — | −37.4x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.5% | 9.5% |
| Last close | $1.28 | $18.49 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $120,780, sold $8,316 | — |
| Piotroski F-score | — | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
MaxCytePrecipio
Operating margin
Percent of revenue
MaxCytePrecipio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MaxCytePrecipio